Human medicines European public assessment report (EPAR): Pelgraz, pegfilgrastim, Date of authorisation: 21/09/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Brinavess, vernakalant hydrochloride, Date of authorisation: 01/09/2010, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Sitagliptin / Metformin hydrochloride Accord, sitagliptin,metformin hydrochloride, Date of authorisation: 22/07/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Vipdomet, alogliptin,metformin, Date of authorisation: 18/09/2013, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Orencia, abatacept, Date of authorisation: 21/05/2007, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Briviact (in Italy: Nubriveo), brivaracetam, Date of authorisation: 13/01/2016, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Beovu, brolucizumab, Date of authorisation: 13/02/2020, Revision: 16, Status: Authorised

Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers for marketing authorisation holders / applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products

Standard operating procedure for validation, publication, and maintenance of real-world data sources and studies in the HMA-EMA RWD Catalogues

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 30, Status: Authorised